118 related articles for article (PubMed ID: 8840484)
1. Modulation of platelet-activating factor synthesis by recombinant interferon-alpha in human renal cell carcinoma.
Imagawa M; Mimata H; Takahashi S; Nakagawa M; Nomura Y; Ogata J
Urol Int; 1996; 57(1):11-6. PubMed ID: 8840484
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
3. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of renal cell carcinoma with interferons].
Oya M
Nihon Rinsho; 2006 Jul; 64(7):1281-5. PubMed ID: 16838645
[TBL] [Abstract][Full Text] [Related]
6. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Kusuda Y; Miyake H; Behnsawy HM; Fukuhara T; Inoue TA; Fujisawa M
Urol Oncol; 2013 Jan; 31(1):42-50. PubMed ID: 21396851
[TBL] [Abstract][Full Text] [Related]
7. Role of platelet-activating factor in two-kidney, one-clip hypertension.
Takahashi S; Imagawa M; Mimata H; Nakagawa M; Ogata J; Nomura Y
Int J Urol; 1997 Jul; 4(4):388-93. PubMed ID: 9256329
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM
J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535
[TBL] [Abstract][Full Text] [Related]
9. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
10. [Advanced renal cell carcinoma showing a different response to two types of interferon-alpha].
Horiguchi A; Uchida A
Nihon Hinyokika Gakkai Zasshi; 2004 Jan; 95(1):50-3. PubMed ID: 14978941
[TBL] [Abstract][Full Text] [Related]
11. Renal necrosis and the involvement of a single enzyme of the de novo pathway for the biosynthesis of platelet-activating factor in the rat kidney inner medulla.
Lee TC; Malone B; Woodard D; Snyder F
Biochem Biophys Res Commun; 1989 Sep; 163(2):1002-5. PubMed ID: 2551264
[TBL] [Abstract][Full Text] [Related]
12. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
13. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
14. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
[TBL] [Abstract][Full Text] [Related]
15. Nephrectomy for metastatic renal-cell cancer.
Bolger G
N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11932483
[No Abstract] [Full Text] [Related]
16. Nephrectomy for metastatic renal-cell cancer.
Copur MS; Ledakis P; Norvell M
N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
[No Abstract] [Full Text] [Related]
17. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy in renal cell carcinoma--comparison of interferon alpha treatment with an untreated control.
Basting R; Corvin S; Händel D; Hinke A; Schmidt D
Anticancer Res; 1999; 19(2C):1545-8. PubMed ID: 10365142
[TBL] [Abstract][Full Text] [Related]
20. A survey of therapy for advanced renal cell carcinoma.
Basso M; Cassano A; Barone C
Urol Oncol; 2010; 28(2):121-33. PubMed ID: 19576800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
